View More Recent Stories
-
ORIC Pharmaceuticals Inc. (ORIC) Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations
-
H.C. Wainwright Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)
-
Stifel Starts ORIC Pharamceuticals (ORIC) at Buy
-
ORIC Pharamceuticals (ORIC) PT Lowered to $15 at Oppenheimer
-
ORIC Pharmaceuticals, Inc. (ORIC) Misses Q2 EPS by 4c
-
ORIC Pharma (ORIC) Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cance
